

Cell and Gene Therapy Tools and Reagents: Global Markets

Market Research Report | 2026-02-05 | 175 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

The report provides an overview of the global market for cell and gene therapy tools and reagents. It includes global revenue (\$ millions) for the base year 2024, estimated data for 2025, and forecast data from 2026 through 2030. In this report, the market is segmented based on product type, application and end user. By product type, the market is segmented into vectors, GMP proteins, GMP antibodies, GMP small molecules, bioreactors, multiplex immunoassays, immunoassays, leukapheresis, cell separation, cell expansion, cytokine release syndrome (CRS) monitoring, cryopreservation and media.

The application segment covered cancer, rare diseases and other diseases. By end user, the market is divided into pharmaceutical and biotechnology companies, academic research institutes, and clinical laboratories.

The regions covered in this study are North America, Europe, Asia-Pacific and rest of the World (RoW) (which includes the Middle East and Africa and South America), with analysis of the markets in the U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, the rest of Europe, China, Japan, India, South Korea and the rest of Asia-Pacific. The report covers the trends and challenges that affect the market. It includes an analysis of the competitive landscape, with the ranking of leading companies and their market shares. The report also has a dedicated section of company profiles that covers details of leading companies. It analyzes companies' environmental, social and corporate governance (ESG) initiatives.

Report Includes

- 77 data tables and 55 additional tables
- An overview of the global market for cell and gene therapy tools and reagents
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2025. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Evaluation of the current market size and revenue growth prospects specific to the cell and gene therapy tools and reagents market, accompanied by a market share analysis by type, application, end user, and region
- Analysis of current and future demand in the cell and gene therapy tools and reagents market, along with a detailed analysis of

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

the competitive environment, market regulations and reimbursement practices

- Discussion of the prevalence of infectious disease, metabolic disorders and chronic ailments, along with the recent technological advances, competitive landscape, and the industry value chain
- Analysis of drivers, challenges, and opportunities affecting market growth
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Market share analysis of the key market participants in the industry, along with their research priorities, product portfolios, global rankings and company competitive landscape
- Profiles of major companies within the industry, including Thermo Fisher Scientific Inc., Cytiva (Danaher Corp.), Merck KGaA, Miltenyi Biotec, and Sartorius AG

Executive Summary

Summary:

The global market for cell and gene therapy tools and reagents is expected to grow from \$12 billion in 2025 and is projected to reach \$19.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2025 to 2030.

Cell and gene therapies (CGTs) utilize cellular or genetic resources to treat or prevent diseases, offering a developing translational technique in precision medicine that has the potential to cure diseases that were previously considered incurable.

According to the article by Jian et al. (2025), published in Cancer Letters, since 2021, the global market for cell and gene therapy tools and reagents has experienced rapid growth. In 2024, there were REDACTED cell and gene therapy (CGT) developers, representing a 6% yearly increase. Currently, REDACTED clinical studies are active, in the areas of rare diseases (REDACTED%) and oncology (REDACTED%). Multiple approvals from global regulators highlighted significant achievements in 2024.

The U.S. Food and Drug Administration (FDA), China's National Medical Products Administration (NMPA), the European Union's European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) have approved a record 13 novel cell and gene therapies (CGTs), making 2024 a pivotal year for therapeutic advances in human diseases. The first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) therapy, the first magnetic resonance imaging (MRI)-guided intracranial adeno-associated virus (AAV) delivery gene therapy and the first tumor infiltration lymphocyte therapy are a few developments that occurred in 2024. These developments marked the beginning of a whole new phase in the practical application of advances in gene editing and cell technologies.

The growing focus on clinical and commercial activities in the CGT sector is expected to drive the global market for cell and gene therapy tools and reagents.

Table of Contents:

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Regional Market Insights
Emerging Technologies
Conclusion
Chapter 2 Market Overview
Cell and Gene Therapy Overview
Cell Therapy
Gene Therapy
Types of Cell and Gene Therapy
Gene Therapy
Cell Therapy
Common Equipment Used
Approved Cell and Gene Therapy Products
Macroeconomic Factors Analysis
Demographic Factors
Geopolitical Factors
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Investments in CGT Research
Expanding Clinical and Commercial CGT Products
Rising Demand for Precision Medicine
Capacity Expansions for Clinical and Commercial Manufacturing
Growing Number of Strategic Initiatives
Rising Aging Population and the Increasing Prevalence of Chronic Diseases
Market Restraints/Challenges
Complex Manufacturing and Supply Chain
High Cost of Development
Lack of Skilled Workforce
Regulatory Hurdles
Market Opportunities
Rising Demand for CGTs in Emerging Countries
Growing Demand for Off-the-Shelf Products
Chapter 4 Regulatory Landscape
Overview
U.S.
Cell Therapy Regulations
Gene Therapy Regulations
Viral and Non-Viral Vectors
Media
GMP Proteins and Antibodies
Leukapheresis
Europe
Asia-Pacific
Chapter 5 Emerging Technologies and Developments
Key Takeaways

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Closed and Automated Systems
Single-Use Technologies and Miniaturization
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Product Type
Key Takeaways
Immunoassays
Bioreactors
Leukapheresis
GMP Antibodies
Multiplex Immunoassays
Vectors
Cell Separation
Cryopreservation
Cell Expansion
Media
GMP Proteins
GMP Small Molecules
CRS Monitoring
Market Analysis by Application
Key Takeaways
Cancer
Rare Diseases
Other Diseases
Market Analysis by End User
Key Takeaways
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Clinical Laboratories
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Analysis
Strategic Initiatives
Agreements, Collaborations and Partnerships
Acquisitions
Investments and Expansions
Chapter 8 Sustainability in Global Market for Cell and Gene Therapy Tools and Reagents: An ESG Perspective
Introduction to ESG
Sustainability Trends and Company Initiatives
Environmental Factors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Social Factors
Governance Factors
Social and Governance Initiatives
Concluding Remarks
Chapter 9 Appendix
Research Methodology
Sources
Abbreviations
Company Profiles
ABCAM LTD.
ADVERUM BIOTECHNOLOGIES INC.
AKRON BIOTECH
BIO-RAD LABORATORIES INC.
BIO-TECHNE
CYTIVA
FUJIFILM IRVINE SCIENTIFIC (FUJIFILM BIOSCIENCES)
MERCK KGAA
MILTENYI BIOTEC
PROTEINTECH GROUP INC.
QIAGEN
REVVITY
SARTORIUS AG
STEMCELL TECHNOLOGIES
THERMO FISHER SCIENTIFIC INC.
Emerging Startups/Market Disruptors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cell and Gene Therapy Tools and Reagents: Global Markets

Market Research Report | 2026-02-05 | 175 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-08"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com